Atrium Health Wake Forest Baptist Hayworth Cancer Center
High Point, North Carolina, 27262, United States
Location status: Recruiting
Location contact
Sheri Whittington
CONTACT
Stephanie Parker, MS
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07324577
The purpose of this study is to evaluate the use and functionality of virtual reality (VR) during radiation therapy treatments for patients with prostate, breast, lung, or head and neck cancer.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
High Point, North Carolina, 27262, United States
Location status: Recruiting
Sheri Whittington
CONTACT
Stephanie Parker, MS
PRINCIPAL_INVESTIGATOR
This is a randomized controlled trial that will assess the feasibility, acceptability, tolerability, and initial clinical efficacy of using a VR device during radiation therapy for participants with prostate cancer, breast cancer, lung cancer, or head and neck cancer.
Participants will be randomized 2:1 to either the VR device intervention arm or the standard of care control arm.
Participants will undergo pre-study assessments, assessments before and after the first radiation treatment, every 6th radiation treatment, and at the end of treatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Patients:
Inclusion criteria
Exclusion criteria
Radiation Therapists:
Inclusion criteria
Radiation therapy for prostate cancer, breast cancer, lung cancer, or head and neck cancer.
Participants will wear the VR headset (Meta Quest 2) during standard of care radiation therapy
Radiation therapists will be asked about their experiences and proficiency with using the VR device.
Time frame: Periprocedural (each treatment visit)
A binary variable (Yes/No) will be created for participants at the level of individual treatment visit to signify whether the participants wore the VR device for the duration of their treatment.
Time frame: Periprocedural (each treatment visit)
VR device functionality (0-2) will be determined at the level of individual treatment visit using the following criteria as determined by the participant and/or treatment staff:
0 = device not functional at any time during the treatment
Time frame: GAD-7: Baseline RTEQ: Periprocedural (After first and last treatment)
Generalized Anxiety Disorder 7-item (GAD-7) to assess pre-existing generalized anxiety and the 23-item Radiotherapy Experience Questionnaire (RTEQ) situational unease and situational repose subscales.
Time frame: At 36 months
Radiation Therapist Survey (Administered to staff only)
Time frame: Periprocedural (each treatment visit)
Total counts and grade of symptoms such as nausea, dizziness, seizures, blurred vision, fatigue, eye or muscle twitching, instability in posture, blackouts triggered by light flashes or patterns, and headache.
Time frame: Periprocedural (first treatment, last treatment, weekly during treatment)
Single Item Anxiety Questionnaire
Time frame: Periprocedural (first treatment, last treatment, weekly during treatment)
Anxiety evaluation with heart rate
Time frame: 4-6 weeks following randomization
VR Satisfaction Questionnaire
Contact information is provided by the study sponsor or research team.
Wake Forest University Health Sciences
Other
Effectiveness of Virtual Reality in the Management of Anxiety for Patients Undergoing Radiotherapy
Acronym: RELAX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07682714
Cancer, Dietary Intake
Minneapolis, Minnesota, United States
View Trial DetailsNCT05648253
Cancer, Neoplasms
Kitchener, Ontario, Canada
View Trial DetailsNCT07598851
Anxiety Disorders, Behavior
Taichung, Taiwan
View Trial DetailsNCT05721053
Cancer, Neoplasms
New York, United States
View Trial Details